David C Fan

US Patent:

7018652, Mar 28, 2006

Filed:

Nov 13, 2003

Appl. No.:

10/714127

Inventors:

Houn Simon Hsia - Irvine CA, US
David Fan - Newport Beach CA, US

Assignee:

Viva America Marketing, Inc. - Costa Mesa CA

International Classification:

A61K 9/20
A61K 9/14
A61K 31/685
A61K 31/355

US Classification:

424464, 424489, 424702, 514458, 514474, 514 78, 514725

Abstract:

Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation and damage to the liver cells. Typically, steatohepatitis involves inflammation of the liver related to fat accumulation, and mimics alcoholic hepatitis but is observed in patients who seldom or never consume alcohol. Nonalcoholic steatohepatitis can lead to serious liver damage, and ultimately cirrhosis. The present invention provides methods and compositions useful for the treatment or alleviation of nonalcoholic steatohepatitis and the pharmaceutical formulations for their administration to a human. Specifically, compositions comprised of lecithin, antioxidants and vitamin B complex are administered parenterally, most preferably by oral administration. Specific therapeutic formulations include admixtures of these compounds and specific dosage formulations include daily oral administrations of these compounds in tablet or powder forms.

US Patent:

20010000028, Mar 15, 2001

Filed:

Nov 29, 2000

Appl. No.:

09/726688

Inventors:

Houn Hsia - Irvine CA, US
David Fan - Newport Beach CA, US

International Classification:

A23L001/30

US Classification:

424/439000, 426/072000, 424/464000, 426/073000, 426/662000, 554/080000, 544/327000, 568/824000, 544/251000, 546/301000, 549/315000, 549/408000

Abstract:

Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation and damage to the liver cells. Typically, steatohepatitis involves inflammation of the liver related to fat accumulation, and mimics alcoholic hepatitis but is observed in patients who seldom or never consume alcohol. Nonalcoholic steatohepatitis can lead to serious liver damage, and ultimately cirrhosis. The present invention provides methods and compositions useful for the treatment or alleviation of nonalcoholic steatohepatitis and the pharmaceutical formulations for their administration to a human. Specifically, compositions comprised of lecithin, antioxidants and vitamin B complex are administered parenterally, most preferably by oral administration. Specific therapeutic formulations include admixtures of these compounds and specific dosage formulations include daily oral administrations of these compounds in tablet or powder forms.

US Patent:

61801399, Jan 30, 2001

Filed:

Dec 4, 1998

Appl. No.:

9/205082

Inventors:

Houn Simon Hsia - Irvine CA
David Fan - Newport Beach CA

Assignee:

Viva America Marketing, Inc. - Costa Mesa CA

International Classification:

A61K 920
A61K 914
A61K 31685
A61K 31355

US Classification:

424464

Abstract:

Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation and damage to the liver cells. Typically, steatohepatitis involves inflammation of the liver related to fat accumulation, and mimics alcoholic hepatitis but is observed in patients who seldom or never consume alcohol. Nonalcoholic steatohepatitis can lead to serious liver damage, and ultimately cirrhosis. The present invention provides methods and compositions useful for the treatment or alleviation of nonalcoholic steatohepatitis and the pharmaceutical formulations for their administration to a human. Specifically, compositions comprised of lecithin, antioxidants and vitamin B complex are administered parenterally, most preferably by oral administration. Specific therapeutic formulations include admixtures of these compounds and specific dosage formulations include daily oral administrations of these compounds in tablet or powder forms.